Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryNov022020	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2020 Financial Results SAN DIEGO , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that the Company will host a conference call and live Read All »	View HTML
Toggle SummaryOct252021	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2021 Financial Results SAN DIEGO , Oct. 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company will host a Read All »	View HTML
Toggle SummaryOct242022	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2022 Financial Results SAN DIEGO , Oct. 24, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will Read All »	View HTML
Toggle SummaryOct252023	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results SAN DIEGO , Oct. 25, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to Read All »	View HTML
Toggle SummaryDec062014	Fate Therapeutics Unveils Preclinical Findings of Newly-Identified Small Molecule Modulator Combination for Ex Vivo Programming of Mobilized Peripheral Blood Expression of Genes Involved in T-cell Function and Hematopoietic Stem Cell Engraftment Significantly Increased Read All »	View HTML Fate Therapeutics Unveils Preclinical Findings of Newly-Identified Small Molecule Modulator Combination for Ex Vivo Programming of Mobilized Peripheral Blood 22.9 KB
Toggle SummaryDec212009	Fate Therapeutics' iPSC Technology Awarded Top Industry Honors for Small Molecule and Protein Reprogramming Breakthroughs San Diego, CA – Fate Therapeutics, Inc. announced today that the Company’s iPSC technology platform, developed with Sheng Ding, Ph.D., has been honored as the Top Innovation of 2009 by The Scientist and has received the 2009 North American Technology Innovation Award from Frost & Read All »	View HTML Fate Therapeutics’ iPSC Technology Awarded Top Industry Honors for Small Molecule and Protein Reprogramming Breakthroughs 12.7 KB
Toggle SummaryOct012013	Fate Therapeutics, Inc. Announces Pricing of Initial Public Offering SAN DIEGO, Oct. 1, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced the pricing of its initial public offering of 6,666,667 shares of its Read All »	View HTML Fate Therapeutics, Inc. Announces Pricing of Initial Public Offering 10.5 KB
Toggle SummarySep302019	Fate Therapeutics Announces the Opening of its cGMP Manufacturing Facility Dedicated to iPSC-derived Cell Therapies State-of-the-Art Facility Designed to use Clonal Master iPSC Lines as Renewable Cell Source for Manufacture of Off-the-Shelf Product Pipeline SAN DIEGO , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the Read All »	View HTML
Toggle SummaryJan102022	Fate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors Multiplexed-engineered CAR NK Cell Product Candidate derived from Clonal Master iPSC Line that incorporates Four Functional Elements, including a Novel CAR Targeting the Pan-tumor Associated Stress Proteins MICA and MICB Proprietary Antigen Binding Domain of FT536 has been Shown to Overcome MICA/B Read All »	View HTML
Toggle SummaryJul092020	Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy FT819 CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus Phase 1 Clinical Study will Evaluate FT819 for Patients with Advanced B-cell Leukemias and Lymphomas SAN DIEGO , July 09, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.